US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.89 ▼-1.02% TSLA $378.69 ▲+2.18% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Viatris Inc. - Common Stock (NQ:VTRS)

17.61 +0.01 (+0.09%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗
ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Viatris Inc (NASDAQ:VTRS) Beats Q4 2025 Estimates and Completes Strategic Review ↗
Via Chartmill
News headline image
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗
Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry. 
Via The Motley Fool
News headline image
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?
Viatris has had an impressive run over the past six months as its shares have beaten the S&P 500 by 34.7%. The stock now trades at $14.11, marking a 37.8% ga... 
Via StockStory
Topics Stocks
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceu... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bastion Bets on Government Spending with $8 Million New Stake in Parsons ↗
Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond. 
Via The Motley Fool
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of... 
Via StockStory
News headline image
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates
In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
2 Value Stocks Worth Your Attention and 1 We Brush Off
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful... 
Via StockStory
News headline image
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a... 
Via Finterra
Topics Economy World Trade
News headline image
Why Viatris (VTRS) Stock Is Up Today
Shares of medication company Viatris (NASDAQ:VTRS) jumped 6.4% in the afternoon session after investment bank UBS upgraded the company's stock from "Neutral" to "Buy" and increased its price target. 
Via StockStory
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
Monday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
3 Unprofitable Stocks with Questionable Fundamentals
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Topics Electric Vehicles
News headline image
3 Reasons to Sell VTRS and 1 Stock to Buy Instead
What a time it’s been for Viatris. In the past six months alone, the company’s stock price has increased by a massive 41.5%, reaching $13.07 per share. This was partly due to its solid quarterly... 
Via StockStory
News headline image
3 Cash-Producing Stocks with Questionable Fundamentals
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Thursday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
3 Volatile Stocks We Keep Off Our Radar
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
News headline image
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of... 
Via Finterra
Topics Earnings Economy Intellectual Property
These S&P500 stocks are moving in today's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >